Intravitreal bevacizumab versus ranibizumab: Effects on the vessels of the fellow non-treated eye

Abstract

Purpose To evaluate the effects of anti-vascular endothelial growth factors (anti-VEGF) on the vessels of the non-treated eyes following intravitreal injections. Methods In this prospective, non-randomized trial, a total of 38 patients were recruited. 21 patients received ranibizumab, and 17 patients received bevacizumab. Fundus photography was carried out at baseline immediately before injection and at 3 days, 7 days, and one month after the injections. Using image analysis software, measurements were summarized as the central retinal artery equivalent (CRAE) and central retinal vein equivalent. Results In non-treated eyes, CRAE decreased significantly from 153.23 ± 15.20 μm before injection to 148.77 ± 17.21 μm 3 days after intravitreal bevacizumab ( P = 0.004). There was no significant difference in CRAE, between the pre-injection baseline, one week, and one month after intravitreal bevacizumab injection in non-treated eyes ( P > 0.05). No significant difference was noted in CRAE in the non-treated eyes of the ranibizumab group at any post-injection visit ( P = 0.1). Conclusion A significant transient narrowing effect of bevacizumab on retinal arterioles in the fellow non-treated eyes on the third day after intravitreal injection may show that plasma concentrations of these drugs are sufficient to spread the effect to the other eye.

Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology

“…Although both molecules bind to VEGF and inhibit its action, 28,29 some authors mention that it could be a difference in affinity and potency between ranibizumab and bevacizumab, 67 whereas others researchers declared there is no enough statistical significance to prove it. [68][69][70][71] In turn, bevacizumab has demonstrated a comparable efficacy and a considerably lower cost than ranibizumab when both formulations are administered via intravitreal injections. 66,72 Aflibercept (Eylea ® ) is a RFP (115 kDa) obtained by combining the Fc portion of a full monoclonal antibody and the two highest affinity domains of VEGFR1 and VEGFR2 34 that binds strongly to VEGF and PGF.…”

“…Although both molecules bind to VEGF and inhibit its action, 28,29 some authors mention that it could be a difference in affinity and potency between ranibizumab and bevacizumab, 67 whereas others researchers declared there is no enough statistical significance to prove it 68‐71 . In turn, bevacizumab has demonstrated a comparable efficacy and a considerably lower cost than ranibizumab when both formulations are administered via intravitreal injections 66,72 …”

Quantitative Analysis of OCT for Neovascular Age-Related Macular Degeneration Using Deep Learning

“…29,53 Furthermore, systemic absorption of anti-VEGF drugs has been suggested to decrease VEGF activity in second-treated eyes, possibly resulting in decreased exudation. [54][55] Drusen was the only segmented feature that presented greater volumes in secondtreated eyes when compared with first-treated eyes (P < 0.05). This could be explained not only by earlier disease detection in second-treated eyes but also by the natural progression of dry AMD before conversion, which in both cases results in a greater drusen volume.…”

Gambaran Tajam Penglihatan Sebelum Dan Sesudah Injeksi Bevacizumab Pada Pasien Retinopati Diabetik Di Rumah Sakit Umum Daerah Dr. Zainoel Abidin Banda Aceh

“…Pada penelitian yang dilakukan oleh Ileya et al ditemukan pasien perempuan lebih banyak menderita retinopati diabetik. 6 Penelitian yang dilakukan oleh G.Y. Ozawa et al menemukan bahwa laki-laki lebih rentan untuk menderita retinopati diabetik dikarenakan fungsi neuroretinal lebih abnormal pada laki-laki yang menderita diabetes tipe 2.…”